As the Department of Health and Human Services considers changes to the federal 340B drug program, including switching mandatory drug manufacturer contributions from discounts to rebates, it is important for policymakers to recognize the myriad concerns with this program.
On March 5, Speaker Ryan moderated a panel on tax policy with AEI’s Alex Brill and Kyle Pomerleau.
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
While the details of future federal legislation and executive actions to legalize, regulate, and tax cannabis remain unknown, such policies could have significant impacts on the federal budget.
Our plan seeks to achieve long-term fiscal stability and promote economic growth by aligning federal spending and revenue and pursuing market-based policy reforms.
